Qilu Pharmaceutical's ADC Pipeline Gains Momentum: 10 First-in-Class Drugs Enter Clinical Trials, Targeting Resistance in Solid Tumors

In 2026,Qilu PharmaceuticalInnovation R&D enters a period of concentrated harvest, and pipeline strength achieves leapfrog upgrade. According toMoxie Medical DatabaseStatistics, since the beginning of this yearQilu Pharmaceutical(Including subsidiaries) A total of 15 Class 1 new drugs have been approved for clinical trials, 10 of which were approved for the first time, including 3 ADC new drugs.

1. Qilu Pharmaceutical's ADC Pipeline Explodes, 7 New Drugs Enter Clinical Trials

In recent years,Qilu PharmaceuticalFocusing on unmet clinical needs, continuously tackling the core technologies of high-end biologics, and building a mature, iterative self-developed ADC platform. At the same time, relying on diversified external collaborations to constantly address technical shortcomings, creating an innovative ADC pipeline with diverse targets and technical differentiation, precisely solving clinical pain points such as difficult-to-treat and drug-resistant solid tumors.

InQilu PharmaceuticalIn the ADC pipeline, the fastest progressing drug is QLC5508 for injection. This drug targets B7-H3, a popular target highly expressed in solid tumors. Its indications for small cell lung cancer, esophageal squamous cell carcinoma, and prostate cancer have been included in the CDE’s breakthrough therapy designation list. Currently, the indications for small cell lung cancer and esophageal squamous cell carcinoma have advanced to Phase III clinical trials, placing the overall progress at the forefront of similar drugs in China.

Source: Mesentech Medicine - Global Drug Research and Development Database

Updated Phase I data presented at the 2025 World Conference on Lung Cancer showed that QLC5508, used for previously treated extensive-stage small cell lung cancer, demonstrated excellent overall safety, significant anti-tumor activity, and the potential to provide long-term survival benefits for patients with advanced refractory disease, fully validating its clinical value.

Another core product, QLS5132, also stands out with remarkable highlights. It is the first CLDN6-targeted ADC drug in China to enter clinical trials, marking a significant breakthrough in the field of novel-target ADCs produced in China. Phase I clinical data presented in an oral report at the 2026 AACR Annual Meeting showed that QLS5132, used for advanced platinum-resistant ovarian cancer, demonstrated good safety, strong, and stable anti-tumor activity. Currently, two clinical trials in China are proceeding steadily, with the fastest progress reaching Phase Ib/II. Meanwhile, the drug has received FDA approval for clinical trials in the United States, successfully initiating its international expansion.

Source: Mesentech Medicine - Global Drug R&D Database

In addition to the above varieties,Qilu PharmaceuticalThree New ADC Products Approved for Clinical Trials This Year: QLS5316 Injection, QLS5308 Injection, and QLS5212 Injection. These three drugs are respectively focused on bispecific antibody-drug conjugates (ADCs), novel differentiated targets for solid tumors, covering various types of advanced refractory solid tumors, further enriching the company's ADC technology pipeline and indication layout.

In addition, the clinical development of two innovative ADCs, QLS5133 and QLC5513, is proceeding steadily. As of now,Qilu PharmaceuticalSeven ADC innovative drugs have entered the clinical stage, forming a multi-target, multi-technology, and multi-indication three-dimensional R&D pattern.

II. Ten Class 1 New Drugs Approved for Clinical Trials for the First Time, Marketed New Drugs Show Strong Growth

Qilu PharmaceuticalCurrently, there are over 100 innovative drugs under research and development, with more than 30 novel Class 1 drugs in clinical development stages, covering multiple disease areas such as oncology, autoimmune disorders, metabolic diseases, cardiovascular and cerebrovascular conditions, and central nervous system disorders. In the field of oncology, the company has established a product portfolio encompassing cutting-edge technologies such as ADCs, bispecific antibodies, and small molecule targeted therapies.

According toMoxie Medical DatabaseStatistics, since 2026,Qilu Pharmaceutical(Including subsidiaries) have received clinical approval for 15 Class 1 new drugs, 10 of which were approved for the first time, marking an accelerated harvest period for the innovative pipeline.

Source: Mosana Medicine - China Drug Evaluation Database

More notably, the two Class 1 new drugs launched by the company in recent years have demonstrated strong market explosiveness. The chemical Class 1 new drug Ilualke Tablets, approved in 2023, achieved sales revenue of over 125 million yuan in all-terminal hospitals in 2025, with a year-on-year increase of 654.02%. The biological Class 1 new drug Eparalil Tovorolimab Injection, approved in 2024, reached sales revenue of 147 million yuan in all-terminal hospitals in 2025, with a year-on-year growth rate of 6647%. The rapid market uptake of these two products not only validates the company's commercialization capabilities but also provides robust support for advancing its subsequent innovative pipeline.

       Title: Qilu Pharmaceutical's ADC Cluster Breakthrough: 10 Novel Class 1 Drugs Approved for Clinical Trials for the First Time, Targeting Drug Resistance in Solid Tumors